| Bioactivity | NLRP3-IN-19 (JT001) is a potent, specific and orally active inhibitor of NLRP3. NLRP3-IN-19 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. NLRP3-IN-19 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis[1]. |
| Name | NLRP3-IN-19 |
| CAS | 2238819-65-1 |
| Formula | C19H22N4O4S |
| Molar Mass | 402.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Povero D, et, al. Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. J Pharmacol Exp Ther. 2023 Aug;386(2):242-258. |
NLRP3-IN-19
CAS: 2238819-65-1 F: C19H22N4O4S W: 402.47
NLRP3-IN-19 (JT001) is a potent, specific and orally active inhibitor of NLRP3. NLRP3-IN-19 can inhibit NLRP3 inflammaso
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.